InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+16.2%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Beaurang Pierre, Directeur Commercial. Officer active across 1 company, notably Nurix Therapeutics, Inc.. Aggregated, 8 reports have been recorded. History available since 10 May 2021. The latest transaction was disclosed on 10 August 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
7,500 shares@ US$1.110.0004% mcap12.8% of flowCommon StockSEC:0001209191-21-050976:0
7,500 shares@ US$1.1112.8% of flowCommon StockSEC:0001209191-21-050976
7,500 shares@ US$1.110.0004% mcap12.6% of flowCommon StockSEC:0001209191-21-046362:0
7,500 shares@ US$1.1112.6% of flowCommon StockSEC:0001209191-21-046362
7,500 shares@ US$1.110.0004% mcap12.3% of flowCommon StockSEC:0001209191-21-039810:0
7,500 shares@ US$1.1112.3% of flowCommon StockSEC:0001209191-21-039810
7,500 shares@ US$1.110.0004% mcap12.3% of flowCommon StockSEC:0001209191-21-031891:0
7,500 shares@ US$1.1112.3% of flowCommon StockSEC:0001209191-21-031891
8 of 8 declarations
About Beaurang Pierre
Pierre Beaurang is the Chief Business Officer at Nurix Therapeutics, Inc. In this role, he is responsible for the business strategy and growth of the company. With a strong background in the biopharmaceutical sector, he plays a key role in expanding operations and innovating products. His leadership is essential to achieving the company's objectives.
